Moderna, Inc.’s Stock Price Skyrockets to $26.20, Marking a Stellar 6.94% Increase

Moderna, Inc. (MRNA)

26.20 USD +1.70 (+6.94%) Volume: 10.99M

Moderna, Inc.’s stock price demonstrates a robust performance, currently trading at 26.20 USD, marking an impressive +6.94% increase this session. Despite a YTD drop of -36.99%, the high trading volume of 10.99M underscores the market’s sustained interest in MRNA shares.

Latest developments on Moderna, Inc.

Moderna’s stock price movements today are influenced by various factors, including a German recommendation for its mRESVIA RSV jab and positive Phase 3 results for its combined COVID-Flu vaccine. Despite a 31.8% decline in Q1, analysts are optimistic about the company’s future, with Morgan Stanley issuing a pessimistic forecast but adjusting the price target. Recent acquisitions and sales of Moderna shares by investment firms like Aviva PLC and Himension Capital Singapore PTE. LTD. also impact the stock price. With Moderna set to report its first quarter 2025 financial results soon, investors are closely watching for key details that could further impact the stock’s performance.

Moderna, Inc. on Smartkarma

Analyst coverage of Moderna on Smartkarma by Baptista Research reveals a mix of perspectives on the biotech giant. In one report titled “Moderna Inc.: Is Its mRNA Platform Fueling A Multi-Billion-Dollar Pipeline Beyond COVID?”, the company’s financial results for 2024 were highlighted, showing both opportunities and challenges. Despite a 53% decrease in total revenue attributed to declining product sales, Moderna recorded a net loss of $3.6 billion, a slight improvement from the previous year.

Another report from Baptista Research titled “Moderna Inc.: Expanding Global Presence For Unmatched Impact! – Major Drivers” focuses on the company’s financial results for the third quarter of 2024. Moderna delivered $1.9 billion in revenue with a net income of $13 million, ending the quarter with $9.2 billion in cash and investments. This solid financial position underscores Moderna’s robust liquidity, providing a strong foundation for ongoing and future initiatives.

A look at Moderna, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Moderna, Inc. is showing promising signs for long-term growth and value, with strong scores in Value and Resilience according to Smartkarma Smart Scores. The company’s focus on developing messenger RNA therapeutics and vaccines for various diseases positions it well for future success. While its Dividend and Growth scores are not as high, Moderna’s Momentum score suggests positive movement in the market.

With a solid foundation in biotechnology and a strategic focus on mRNA medicines, Moderna, Inc. appears to have a bright outlook ahead. Its high scores in Value and Resilience indicate a strong position in the industry, while the company’s emphasis on developing therapies for infectious, immuno-oncology, and cardiovascular diseases showcases its commitment to innovation and addressing critical healthcare needs.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma